Walleye Trading
MRNA icon

Walleye Trading’s Moderna MRNA Stock Holding History

Walleye Trading’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.5M Buy
737,500
+35,200
+5% +$1.64M 0.06% 306
2025
Q4 		$20.7M Sell
702,300
-458,400
-39% -$12.5M 0.03% 599
2025
Q3 		$30M Buy
1,160,700
+480,200
+71% +$13.4M 0.05% 428
2025
Q2 		$18.8M Buy
680,500
+146,600
+27% +$3.86M 0.03% 553
2025
Q1 		$15.1M Buy
533,900
+198,600
+59% +$7.05M 0.04% 542
2024
Q4 		$13.9M Buy
335,300
+248,200
+285% +$11.9M 0.03% 628
2024
Q3 		$5.82M Sell
87,100
-32,900
-27% -$3.02M 0.01% 1052
2024
Q2 		$14.3M Buy
120,000
+4,600
+4% +$582K 0.03% 522
2024
Q1 		$12.3M Sell
115,400
-120,900
-51% -$12.2M 0.03% 610
2023
Q4 		$23.5M Sell
236,300
-25,400
-10% -$2.14M 0.05% 385
2023
Q3 		$27M Buy
261,700
+45,000
+21% +$5.02M 0.07% 274
2023
Q2 		$26.3M Sell
216,700
-106,600
-33% -$14.2M 0.08% 222
2023
Q1 		$49.7M Sell
323,300
-127,200
-28% -$21M 0.11% 141
2022
Q4 		$80.9M Buy
450,500
+121,800
+37% +$19.9M 0.23% 53
2022
Q3 		$38.9M Buy
328,700
+30,400
+10% +$4.61M 0.12% 147
2022
Q2 		$42.6M Buy
298,300
+52,500
+21% +$7.5M 0.14% 111
2022
Q1 		$42.3M Buy
245,800
+48,700
+25% +$8.2M 0.14% 128
2021
Q4 		$50.1M Buy
197,100
+58,100
+42% +$17M 0.16% 116
2021
Q3 		$53.5M Sell
139,000
-6,200
-4% -$2.29M 0.19% 81
2021
Q2 		$34.1M Buy
145,200
+47,500
+49% +$8.49M 0.13% 118
2021
Q1 		$12.8M Buy
97,700
+83,900
+608% +$12.2M 0.06% 246
2020
Q4 		$1.44M Buy
13,800
+7,200
+109% +$728K 0.01% 1665
2020
Q3 		$467K Sell
6,600
-15,800
-71% -$1.1M ﹤0.01% 2300
2020
Q2 		$1.44M Buy
22,400
+9,200
+70% +$504K 0.01% 1373
2020
Q1 		$395K Buy
13,200
+13,100
+13,100% +$301K ﹤0.01% 2057
2019
Q4 		$2K Sell
100
-4,300
-98% -$76.3K ﹤0.01% 4154
2019
Q3 		$70K Buy
+4,400
New +$65K ﹤0.01% 3460

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Trading's MRNA Position: Q1 2026 in Review

Walleye Trading reduced its Moderna (MRNA) stake by 98% in Q1 2026, selling an estimated $14.8M and leaving 7,257 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #2764.

Walleye Trading first reported a position in MRNA in Q2 2019 and has held it in 20 quarters since. The position peaked at $25M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Walleye Trading held 7,257 shares of Moderna worth $369K as of Q1 2026.
  • Walleye Trading sold 316,376 Moderna shares in Q1 2026, an estimated $14.8M.
  • Moderna made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2764 holding.
  • Walleye Trading first reported a position in Moderna in Q2 2019 and has held it in 20 quarters since.
  • Walleye Trading's Moderna position peaked at $25M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.